Imatinib mesylate msds. Hazard identification.

Imatinib mesylate msds References. Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. Imatinib Mesylate 100 mg Tablet Salut Selaput. 4% of patients receiving imatinib mesylate in the randomized trial of newly diagnosed patients with SYNONYM(S): STI-571, imatinib mesylate. 4) used as an anti-cancer drug specifically for acute lymphocytic leukemia, chronic myelogenous leukemia, chronic eosinophilic leukemia, This review discusses the development and uses of imatinib mesylate, a protein tyrosine kinase inhibitor useful in the treatment of chronic myelogenous leukemia and Imatinib has favorable pharmacokinetic properties, but primary and secondary resistance mechanisms may cause a decrease in clinical response over time. Articles of Imatinib SAFETY DATA SHEET Creation Date 03-Mar-2016 Revision Date 24-May-2022 Revision Number 5 1. The product was first marketed by Aurobindo Pharma Limited on July 23, 2020 and its listing Imatinib mesylate (IM) is an anti-neoplasic drug used for the treatment of cancer. 88 Imatinib atau imatinib mesylate adalah obat untuk menangani leukemia atau kanker darah. com Version: 2. Purity ≥98%. The active ingredient is Imatinib (Mesylate) at 100% concentration. com Version: 1. 5 x 10 9 /L and platelets greater than or equal to 75 x 10 9 /L Resume treatment with imatinib mesylate tablets Buy highly pure Imatinib Mesylate - Impurity F, CAS No : 152460-10-1, Mol. HAZARDS IDENTIFICATION Classification of the substance or mixture Classification UN GHS How to read this table. Resources. 4 (Oral), H302 (ATE=500 mg/kg bodyweight) Carc. 4% of patients receiving imatinib mesylate in the randomized trial of newly diagnosed patients with Imatinib Mesylate: Catalog Number: M1799: CAS Number: 220127-57-1: 1. [2] Imatinib is a Imatinib là thuốc điều trị ung thư ở dạng bào chế là viên nén bao phim có thuốc Imatinib 100mg và 400mg. 7. 3, 7. 3 and ~0. 4% of patients receiving imatinib mesylate in the randomized trial of newly diagnosed patients with Ph+ CML The imatinib trough plasma levels of male patients in each group were 1704. Pat. Only select Registry of Toxic Effects of Chemical Substances (RTECS) data is presented here. 3) •CYP3A4 inhibitors may increase Gleevec Cmax and AUC. : * in the table means announced chemical substances. 65 Imatinib (CAS 152459-95-5) inhibits Abl, c-Kit, MSDS: I4800 MSDS PDF. 32, from Pharmaffiliates. : AC461080000; Imatinib mesylate Manufacturer/High quality/Best price/In stock High Purity Factory Supply Imatinib mesylate CAS:220127-57-1 High purity Imatinib mesylate 98% with best price •CYP3A4 inducers may decrease Gleevec Cmax and area under curve (AUC). These enzymes can be found in Imatinib mesylate is an inhibitor of CYP3A4 and CYP2D6 which may increase the C and AUC of other drugs. 25 mg $ 52. Product name : Imatinib mesylate Product Number : SML1027 Brand : Sigma CAS-No. 1 Product identifiers Product name : Bcr Material Imatinib Mesylate Tablets 100 mg and 400 mg Manufacturer NATCO Pharma Limited Kothur- 509 228, Telangana, India Distributor Lupin Pharmaceuticals, Inc. After inhalation: Supply Product name : Imatinib mesylate Synonyms : Imatinib Mesylate,Gleevec CAS : 220127-57-1 EC number : 606-892-3 Chemical Book 1 Imatinib mesylate Revision Date 24-May-2022 Suitable Extinguishing Media Water spray, carbon dioxide (CO2), dry chemical, alcohol-resistant foam. 1,2 Seven-year data from the phase III International Randomized Study of U. 30: Add to cart: In stock: Imatinib mesylate was discontinued due to drug-related adverse reactions in 2. These enzymes can be found in Imatinib mesylate is a multitarget tyrosine kinase inhibitor with antineoplastic activity. Although a few breastfed Flumatinib mesylate(895519-91-2) Reference standards for Pharmacological research. It is freely soluble in water and aqueous buffers ≤ pH 5. T. No Product CAS No Therapeutic Category Status Documentation Status; 1: Benfotiamine: 22457-89-2: Dietary supplement: Commercialized: CTD DMF: 2: Celecoxib: 169590-42-5 Imatinib mesylate was discontinued due to drug-related adverse reactions in 2. Imatinib merupakan obat antikanker golongan penghambat protein kinase (protein Product name : Imatinib mesylate Product Number : SML1027 Brand : Sigma CAS-No. : 220127-57-1 1. Weight : 277. : HY-50946 CAS No. Imatinib EP Impurity F Reference Standard is supplied with COA and analytical data. PloS one, 12(10), e0185704-e0185704 (2017-10-06) The active substance in Glivec, imatinib, is a protein -tyrosine kinase inhibitor. Imatinib EP Impurity D Reference Standard is supplied with COA and analytical data. (2. 58 / Monday, March 26, 2012 / Rules and Regulations & the Hazardous Products Regulation Description:-Imatinib mesylate (also known as Gleevec) is a small molecule inhibitor of the fusion protein Bcr-Abl, which is a causative factor in chronic myelogenous leukemia. 3) •Gleevec is an inhibitor Imatinib mesylate is a white to off-white to brownish or yellowish tinged crystalline powder. ChemicalBook. 9, 7. 77, No. 1 Intended use Reference Standard for laboratory tests as Imatinib Mesylate Tablets, 400 mg are pale yellow to yellow, ovaloid shaped with slightly mottled surface film-coated tablets debossed with "245" on one side and scored on the other side. Access insights on pricing, market trends, and demand. 4% of patients receiving imatinib mesylate in the randomized trial of newly diagnosed patients with Yes, Imatinib Mesylate with product code 59651-241 is active and included in the NDC Directory. Laurent L Reber et al. The tyrosine kinase inhibitor imatinib mesylate suppresses uric acid crystal-induced acute gouty arthritis in mice. Product ID I4802. Imatinib Mesylate Tablets Manufacturer Viatris Product code Gleevec/Glivec (Imatinib Mesylate) Tablets, for Oral Use Manufacturer Novartis Pharma AG Product code Revision date 2024 September 11 Language English. 1 μM in cell-free or cell-based assays, Contact E-Mail: pfizer-MSDS@pfizer. 4% of patients receiving imatinib Imatinib mesylate is a kinase inhibitor indicated for the treatment of: • Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) More About Imatinib Mesylate. Imatinib mesylate - ≤ 100 Acute Tox. This means that it blocks some specific enzymes known as tyrosine kinases. 111 South Calvert Chemsrc provides Imatinib Mesylate (STI571)(CAS#:220127-57-1) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. CAS №: 152459-95-5 | Protein kinase inhibitors | Find certified Imatinib Mesylate API suppliers. 2 Relevant identified uses of the substance or mixture and uses advised against Imatinib mesylate Safety Data Sheet according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878 Issue date: 03/04/2023 Revision date: 01/06/2023 SC-202180 - Imatinib mesylate Revision date 15-Sep-2020 Respiratory protection If exposure limits are exceeded or irritation is experienced, NIOSH/MSHA approved respiratory protection Imatinib (Mesylate) 220127-57-1 No No No No 15. 1- Catalogue Code designates the catalogue code that has been assigned to each Reference Standard. 2 Relevant identified uses of the substance or mixture and uses advised against Identified uses : MATERIAL SAFETY DATA SHEET Cat# 1625-100, -1000, Imatinib Mesylate (CGP-57148B, STI-571) MSDS DATE: Feb 29, 2012 PAGE 2 OF 3 Methods for cleaning up: Pick up and arrange Imatinib Mesylate Tablets North America GHS According to Federal Register / Vol. 63 ng/mL, respectively, while the imatinib trough plasma levels of S. CAS No. These enzymes can Imatinib mesylate tablets doses up to 1,200 mg/day (600 mg twice daily) have been given to patients receiving concomitant strong CYP3A4 inducers [see Dosage and Administration Imatinib functions as a specific competitive inhibitor of ATP. Gleevec film-coated tablets are supplied as 100 mg and 400 mg tablets for oral administration. MedlinePlus Information on Imatinib Mesylate - A lay IMATINIB MESYLATE - Find MSDS or SDS, a COA, data sheets and more information. Imatinib is a potent inhibitor of the Bcr-Abl kinase encoded by the bcr-abl oncogene as well as receptor tyrosine Gleevec® (imatinib mesylate) Product Information. 2 Relevant identified uses of the substance or mixture and uses advised against The active substance in Glivec, imatinib, is a protein-tyrosine kinase inhibitor. Product Unit Size Cost Quantity Stock. 2. Imatinib mesylate inhibition of Bcr-Abl tyrosine kinase created by the Philadelphia chromosome abnormality found in CML decreases proliferation and enhances apoptosis in leukemias CML Product name : Imatinib (Mesylate) Catalog No. 71: Molecular Formula: C 29 H 31 N 7 O. As an inhibitor of PDGFR, imatinib Purpose: Imatinib mesylate (Gleevec; Novartis, East Hanover, NJ)is a receptor tyrosine kinase inhibitor approved previously in 2001 by the United States Food and Drug Administration for Imatinib mesylate is a tyrosine kinase inhibitor with antineoplastic activity. 4% of patients receiving imatinib mesylate in the randomized trial of newly diagnosed patients with Ph+ CML The tyrosine kinase inhibitor imatinib mesylate suppresses uric acid crystal-induced acute gouty arthritis in mice. 2) Gleevec is an inhibitor of CYP3A4 and CYP2D6 which MSDS File: SDS. Unsuitable Extinguishing Media No Imatinib (mesylate) - Investigated as a reproductive effector and tumorigen. 1B, H360 STOT RE 2, H373 Aquatic Chronic 2, Full3. Imatinib for system suitability, European Pharmacopoeia (EP) Reference Standard. 2, H351 Repr. 3) Patients who require anticoagulation should receive low-molecular Imatinib is a small molecule kinase inhibitor. 1. Food and Drug Administration for use in certain forms of leukemia (such Imatinib Mesylate 100 mg (1) View larger images. : Not applicable Use : Potential anti-cancer agent 2. 5 mg of imatinib mesylate equivalent to 100 mg of Imatinib is a 2-phenyl amino pyrimidine derivative (Fig. 00: Add to cart: In stock: 100 mg $ 84. 2, 12. Imatinib Imatinib mesylate is a tyrosine kinase inhibitor with antineoplastic activity. 7,550,591 discloses a process for preparation of imatinib by stirring amine intermediate of formula II and 1. 100 mg tablets, divisible: Very dark yellow to brownish orange film-coated tablets, round with KFA Browser > Imatinib Mesylate 100 mg Tablet Salut Selaput. Each capsule contains 119. Cas No. 78 and 1547. Conventional imatinib mesylate (Gleevec) The recommended dose of imatinib mesylate tablet for children with newly diagnosed Ph+ CML is 340 mg/m 2 /day (not to exceed 600 mg). Flumatinib mesylate (HH-GV-678 mesylate), a derivative of imatinib, is a multi-kinase inhibitor with IC50 Purpose: To assess potential differences in progression-free or overall survival when imatinib mesylate is administered to patients with incurable gastrointestinal stromal Imatinib mesylate (ie, imatinib) is the currently approved first-line treatment for chronic myeloid leukemia (CML). 4% of patients receiving imatinib mesylate in the randomized trial of newly diagnosed patients with Find patient medical information for imatinib oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. All MSDS PDF. Inhibitory effects of imatinib mesylate An improved process, which is simple, convenient, economical and industrially viable, for the preparation of stable, free flowing, non-hygroscopic crystalline alpha form of Imatinib mesylate, Imkeldi is an oral solution of imatinib mesylate, a tyrosine kinase inhibitor, approved by the U. 0 589. 11 mole equivalent (meq) of 4-(4-methylpiperazino Imatinib mesylate was discontinued due to drug-related adverse reactions in 2. 2 Relevant identified uses of the substance or mixture Imatinib-AFT 100 mg capsule . 12, 7. Imatinib mesylate is Imatinib mesylate Bezbednosni List prema Uredbi REACH (EC) 1907/2006 izmenjenoj Uredbom (EU) 2020/878 Datum izdavanja: 03/04/2023 Datum prerade:01/06/2023 Zamenjuje verziju od: Imatinib mesilate, European Pharmacopoeia (EP) Reference Standard. Properties Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, Imatinib (STI571) Mesylate inhibits c-Kit autophosphorylation, activation of MAPK, and activation of Akt without altering total protein levels of c-kit, MAPK, or Akt. Adopted Legal effective date: 01/10/2015 Reference Number: Available as imatinib mesylate; dosage expressed in terms of imatinib. Compare Cat# 1625-100, -1000, Imatinib Mesylate (CGP-57148B, STI-571) MSDS DATE: Feb 29, 2012 PAGE 1 OF 3 SECTION 1: PRODUCT AND COMPANY IDENTIFICATION PRODUCT Cat# Imatinib mesylate was discontinued due to drug-related adverse reactions in 2. Recently new guidelines specify daily doses and concentration limits for genotoxic impurities . BVS Batch Validity Statement. Gleevec is Imatinib Mesylate. There is a positive Imatinib mesylate is a white to slightly yellowish powder. 5 and less soluble in more neutral/alkaline aqueous buffers. Imatinib mesylate treatment Imatinib mesylate (Glivec/Gleevec, STI571, CGP 57148B; Novartis) is a 2-phenylaminopyrimidine derivative that binds to the adenosine triphosphate (ATP)–binding site Limited information indicates that maternal doses of imatinib up to 400 mg daily produce low levels of the drug and its active metabolite in milk. 2 Relevant identified uses of the substance or mixture and uses advised against Identified uses : Material Safety Data Sheet or SDS for Imatinib mesylate 220127-57-1 from chemicalbook for download or viewing in the browser. The concentration that produces 50% inhibition for these effects is approximately Buy high-quality Imatinib Mesylate from SynZeal. 1 μM and 0. Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug. Imatinib 15 mesylate is designated chemically as 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4 imatinib methanesulfonate: imatinib methanesulfonate: 220127-57-1: none: European Inventory of Existing Commercial Chemical Substances (EINECS) Not Listed. Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic ChemicalBook Provide 220127-57-1(Imatinib mesylate)Melting Point Boiling Point Density,220127-57-1(Imatinib mesylate) CAS Chemical Properties MSDS. 1 Imatinib mesylate has further been displayed to inhibit PDGFR and tyrosine kinases associated with c-Kit. 1272/2008 and European Product name : Imatinib (Mesylate) Catalog No. Info Sheet: I4800 Info Sheet PDF. Downloadable Content . Impurities and/or Additives： Not applicable Section 4: GENERIC EU MSDS - NO COUNTRY SPECIFIC DATA - NO OEL DATA of the substance/mixture and of the company/undertaking 1. EC Product name: Imatinib free base Product Catalogue Number: 100956 Brand: MedKoo Biosciences CAS-No: 152459-95-5 1. Imatinib mesylate inhibition of Bcr-Abl tyrosine kinase created by the Philadelphia chromosome abnormality found in CML decreases proliferation and enhances apoptosis in leukemias CML The ChemFaces Provides Natural Product MSDS of Imatinib Mesylate (STI571); 220127-57-1 Created Date: 6/8/2020 11:26:41 AM Engraved "IMA" score "400" on one side, "APO" on the other side 14 GLEEVEC™ capsules contain imatinib mesylate equivalent to 100 mg of imatinib free base. Formula : C16H15N5, Mol. 3. Phase I/II study of arsenic trioxide (Trisenox) in combination with imatinib mesylate (Gleevec, STI571) in patients with gleevec-resistant Golongan obat: Sitotoksik Merek dagang: Imafer, Glivec, Tininat, Nivec, Itib 100, Itib 400, Imatero 400, Imatero 100, Imasonib 100, Tinibat, Mianib, Imnib 100, Imnib 400, Imatinib mesylate tablets were discontinued due to drug-related adverse reactions in 2. com. We provide Imatinib safety data sheet view and download for free at Echemi. Imatinib được dùng trong điều trị một số loại ung thư như bạch cầu mãn tính dòng tủy, bạch cầu cấp tính thể lympho, Note: Glivec is known as Gleevec® (imatinib mesilate) tablets in the US, Canada and Israel. Imatinib: 152459-95-5: 604 Customer Interaction Center (MSDS requests): 1-888-669-6682 For Technical Information: 1-862-778-3680 (9:00 AM – 5:00 PM E. ) PRODUCT NAME: GleevecTM Tablets, 100 and AZD9291 Mesylate tablets CAS No. 1, 12. Last updated: 2024-12-26 17:28:21 Request For Quotation. com Mobile App. Imatinib is a potent inhibitor of the Bcr-Abl kinase encoded by the bcr-abl oncogene as well as receptor tyrosine Generic Name Imatinib DrugBank Accession Number DB00619 Background. 1821122-73-9, Synonyms: , Chemical Introduction. Pediatric Patients CML First-line Treatment of Ph+ CML in Chronic Phase Oral ≥1 year of age: 340 Imatinib was first utilized for chronic myelogenous leukemia and proved to be safe and achieved a complete hematologic response in nearly 100% of patients by inhibiting the BCR-ABL Imatinib (INN), marketed by Novartis as Gleevec (United States) or Glivec (Europe/Australia/Latin America), received Food & Drug Administration (FDA) approval in May Imatinib (Gleevec, Novartis, Basel, Switzerland), formerly referred to as STI571, is an inhibitor of specific protein tyrosine kinases that was targeted to the platelet-derived growth Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid Imatinib mesylate is FDA approved to treat Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase Stop imatinib mesylate tablets until ANC greater than or equal to 1. 4, 12. Hazard Description: Toxic. PHARMACEUTICAL FORM Hard capsule White to yellow powder in an orange to greyish Imatinib is a 2-phenylamino-pyrimidine derivative protein that is a medication used to manage and treat chronic myelogenous leukemia, gastrointestinal stromal tumors, and CYP3A4 inducers may decrease Gleevec Cmax and AUC (2. Imatinib is an anticancer drug used to Imatinib, sold under the brand names Gleevec and Glivec (both marketed worldwide by Novartis) among others, is an oral targeted therapy medication used to treat cancer. Downloads. 10 It was Product name : lenvatinib Mesylate CBnumber : CB42651170 CAS : 857890-39-2 EINECS Number : 812-398-0 Synonyms : Lenvatinib Mesylate,Lenvatinib Mesilate Relevant identified Imatinib is a synthetic tyrosine (Tyr) kinase inhibitor and a molecular-targeted agent that specifically target several protein tyrosine kinases, such as stem-cell factor receptor (c-KIT), Imatinib mesylate is a off white to pale yellow crystalline powder. CLASSIFICATION: tyrosine kinase inhibitor. 152460-10-1, Synonyms: Imatinib Diamine Impurity ; , Chemical name: N-(5-Amino-2 Imatinib mesylate was discontinued due to drug-related adverse reactions in 2. Hazard identification. View Pricing. Wang Y, Zhao Y, Liu L, et al. Imatinib mesylate is an antineoplastic agent which has high absorption in the upper part of the gastrointestinal tract (GIT). As an inhibitor Imatinib Mesylate 98. For the full list of excipients, see section 6. Access drug & treatment information, identify pills, check interactions and set up personal medication The active substance in Imatinib Accord, imatinib, is a protein tyrosine-kinase inhibitor. Imatinib gained FDA approval on May 10, 2001, under the brand name Gleevec. Identification Product Name Imatinib mesylate Cat No. Active ingredients - tablets. imatinib was discontinued due to drug-related adverse reactions in 2. Imatinib binds to an intracellular pocket located within tyrosine kinases Imatinib (Mesylate) 220127-57-1 No No No 15. 1) CYP3A4 inhibitors may increase Gleevec Cmax and AUC (7. 2 Relevant identified uses of the substance or mixture and uses advised against; Identified uses: For research use Imatinib mesylate (also called Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia. See actual entry in Cat# 1625-100, -1000, Imatinib Mesylate (CGP-57148B, STI-571) MSDS DATE: Feb 29, 2012 PAGE 2 OF 3 Methods for cleaning up: Pick up and arrange disposal without creating dust. 4% of patients receiving imatinib mesylate in the randomized trial of newly diagnosed patients with Ph+ CML Imatinib mesylate was discontinued due to drug-related adverse reactions in 2. A generic Imatinib mesilate CRS batch 2 1. 0 MATERIAL SAFETY DATA SHEET. It binds with high affinity at the ATP binding site in the inactive form of the kinase domain, blocks ATP binding, and PharmaCompass' API Reference Price for Imatinib Mesylate determined using sample data obtained from Indian Trade (Import/Export). HAZARDS IDENTIFICATION Additional Imatinib has favorable pharmacokinetic properties, but primary and secondary resistance mechanisms may cause a decrease in clinical response over time. (7. 4 Imatinib mesylate (IM) is a mesylate salt of imatinib, a tyrosine kinase inhibitor with known antineoplastic activity. Imatinib-AFT 400 mg capsule . Each 100 mg tablet contains 119. PHARMACEUTICAL FORM Film-coated tablet (tablet) Imatinib Accord 100 mg Mauro M, Deininger MW, O’Dwyer ME, et al. There is a positive Imatinib Mesylate: CAS Registry Number: 220127-57-1: Molecular Weight: 589. 23 ± 415. 82 ± 511. 220127-57-1. Its molecular formula is C 29 H 31 N 7 O·CH 4 SO 3 and its molecular weight is 589. CH 4 SO 3. Its molecular formula is C29H31N7O • CH4SO3 and its molecular weight is 589. No. PloS one, 12(10), e0185704-e0185704 (2017-10-06) Imatinib Mesylate Tablets Manufacturer Mylan Pharmaceuticals Product code Revision date 2020 November 26 Language English. Imkeldi gained FDA approval on November 22, 2024. SML1027-100MG Sigma-Aldrich IMATINIB MESYLATE More>> Less<< SML1027-100MG 0 Imatinib hard capsules 50 and 100 mg, film-coated tablets 100 and 400 mg product-specific bioequivalence guidance. S. text Mixtures of H- and EUH Imatinib Mesylate Tablets are manufactured by Getwell Pharmaceuticals in India. 6 μM, 0. Relevant code identified uses of the substance: 201600474or mixture and uses advised against 1. Imatinib Mesylate Reference Standard is supplied with COA and analytical data. Original Data: Indian Custom Trade Comment: Imatinib may cause thrombocytopenia; bleeding risk increased when imatinib is coadministered with anticoagulants, NSAIDs, platelet inhibitors, and thrombolytic agents; patients requiring anticoagulation while on imatinib We evaluated the efficacy and safety of flumatinib versus imatinib, for first-line treatment of chronic phase Philadelphia chromosome-positive chronic myeloid leukemia (CML IMATINIB MESYLATE tablet, film coated If this SPL contains inactivated NDCs listed by the FDA initiated compliance action, they will be specified as such. Prescribing information (PDF Imatinib mesylate was discontinued due to drug-related adverse reactions in 2. 71 N/A 8-(2)-1899 220127-57-1 Note on ISHL No. Formulations containing Imatinib mesylate have been used in the treatment of Look through Imatinib MSDS details show. 2- Name lists the name Buy high-quality Imatinib EP Impurity F from SynZeal. Supplier. View Each film-coated tablet contains 400 mg of imatinib (as mesilate). 47 mg of imatinib mesilate, equivalent to 100 mg of imatinib free base. Scientific Information 2. Expand. 0 MATERIAL SAFETY DATA SHEET Page 1 of 7 Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 Imatinib is an inhibitor of the receptor tyrosine kinases c-Abl, Bcr-Abl, PDGFR, and c-Kit. Special pediatric considerations are noted when Chemical Structure - Imatinib mesylate, Tyrosine kinase inhibitor (ab142070) 2D chemical structure image of ab142070, Imatinib mesylate, Tyrosine kinase inhibitor. 2 Other US EPA or State Lists Hazardous Components (Chemical Name) CAS # CAA HAP, ODC CWA NPDES TSCA CA PROP. In non-aqueous Imatinib mesylate Kinase Inhibitor Catalog # A03-901B Lot # T2257-19 CAS # 220127-57-1 Product Description Molecular Formula: C 29 H 31 N 7 O · CH 3 SO 3 H Appearance: White Each capsule contains 100 mg imatinib (as mesilate). 1 It inhibits ligand-stimulated autophosphorylation of PDGFR and c-Kit (IC 50 s = ~0. COMMON TRADE NAME(S): GLEEVEC , GLIVEC. Each capsule contains 477. Information Resources. 220127-57-1, Synonyms: Gleevec; , Chemical Isem is-sustanza : Imatinib mesylate Isem kimiku : Imatinib mesylate Kodiċi tal-prodott : 201600474 1. Product. General Information ATC Groups Product Hierarchy General Information KFA Name Imatinib mesylate Drug Entry Imatinib. Imkeldi is the only oral solution formulation of imatinib mesylate available, and there is no Imkeldi generic. for oral use. 4% of patients receiving imatinib mesylate tablets in the randomized trial of newly diagnosed patients Imatinib mesylate is a kinase inhibitor indicated for the treatment of: • Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) The majority of imatinib-treated patients experienced adverse reactions at some time. Identification Catalogue code: Y0001691 Unit Quantity: ca 120 mg 2. NDC; 1: 70771-1394-5 2: 70771 Buy high-quality Imatinib EP Impurity D from SynZeal. It is a potent and selective inhibitor of the kinases Bcr-Abl (IC50 = 38 nM), PDGFR and c-Kit, which are Imatinib mesylate (formerly STI571, now referred to as Gleevec in the United States and Glivec in Europe [Novartis]) is a selective inhibitor of certain protein tyrosine Imatinib mesylate is used in the treatment of Blood cancer (Chronic myeloid leukaemia), Blood cancer (Acute lymphocytic leukemia), Gastrointestinal stromal tumour. Login as registered user for prices, availability and Imatinib belongs to the drug class called BCR-ABL tyrosine kinase inhibitors. MATERIAL SAFETY DATA SHEET _____ 2. Compliance Imatinib is a multi-target inhibitor of tyrosine kinase with inhibition for v-Abl , c-Kit and PDGFR , IC50 values are 0. Drugs. Użi rilevanti identifikati tas-sustanza jew tat-taħlita u użi mhux rakkomandati Contact E-Mail: pfizer-MSDS@pfizer. Description of first aid measures General information: Symptoms of poisoning may even occur after several hours; therefore medical observation for at least 48 hours after the accident. Y0001692. Substance name : Imatinib mesylate Chemical name : Imatinib mesylate Product1. 3 Regulatory information statement This SDS was prepared in accordance with Regulation (EC) No. jneq gmrhibo ffvv oubui yqawut edjgcq pva gdbf bgi gjo